Alkermes earnings release, July 28, 2026

Alkermes plc. (ALKS) · Form 8-K, Item 2.02 · Filed · SEC filing

Alkermes plc Reports Second Quarter 2026 Financial Results — Second Quarter Revenues of $496.0 Million — — GAAP Net Income of $0.5 Million and Adjusted EBITDA of $139.2 Million — — Blair Jackson to Assume Chief Executive Officer Role on August 1, 2026; Richard Pops to Continue as Chairman of the Board of Directors — DUBLIN, July 28, 2026 — Alkermes plc

(Nasdaq: ALKS) today reported financial results for the second quarter of 2026.

“The second quarter was marked by strong commercial performance and meaningful progress across our pipeline as we continued to execute on our strategic priorities. Our commercial portfolio consists of differentiated products that are positioned to generate substantial revenue and cash flow for years to come. At the same time, our orexin 2 receptor agonist portfolio represents a potentially transformational growth opportunity for Alkermes and positions us at the forefront of one of the most exciting new therapeutic categories in neuroscience,” said Richard Pops, Chairman and Chief Executive Officer of Alkermes. “As I prepare to transition the Chief Executive Officer role, I do so with tremendous pride in what this organization has achieved and great optimism for its future. Blair and the leadership team are well positioned to build on this momentum and lead Alkermes through its next phase of growth, innovation and value creation, and I look forward to supporting them in my continuing role as Chairman.”

“As we move into the second half of the year, we have clear priorities and a sharp focus on execution. With our first ADHD data for ALKS 7290 expected in the coming months and topline results from our alixorexton phase 2 idiopathic hypersomnia study expected toward year-end, we are generating significant new datasets that may open new opportunities for our orexin 2 receptor portfolio,” said Blair Jackson, Chief Operating Officer of Alkermes. “With a talented team, a strong financial foundation and exciting opportunities ahead in sleep medicine and across our neuroscience portfolio, I am honored to step into the CEO role and continue building on the strong foundation for growth that Richard and the entire organization have established.”

Key Financial Highlights

Revenues

Profitability¹

Revenue Highlights

Proprietary Product Revenues

• LYBALVI revenues for the quarter were $94.0 million. Revenues and total prescriptions grew 12% and 18%, respectively, compared to the second quarter of 2025.

• ARISTADA i revenues for the quarter were $96.7 million. During the quarter, the company recorded ARISTADA revenue of approximately $4 million related to gross-to-net favorability, primarily driven by favorable patient mix.

• VIVITROL revenues for the quarter were $124.5 million. During the quarter, the company recorded VIVITROL revenue of approximately $4 million related to gross-to-net favorability, primarily driven by favorable patient mix.

• LUMRYZ revenues for the quarter were $96.6 million, which included approximately $7 million of inventory benefit due to timing of shipments.

Manufacturing & Royalty Revenues

• VUMERITY® manufacturing and royalty revenues for the quarter were $30.6 million.

• Royalty revenue from XEPLION®, INVEGA TRINZA®

/TREVICTA® and INVEGA HAFYERA®

/BYANNLI® for the quarter were $27.5 million.

• Manufacturing revenue from RISPERDAL CONSTA® for the quarter was $20.9 million.

Key Operating Expenses

(1)

Includes $20.2 million of share-based compensation expense related to the acceleration of vesting of equity awards for former Avadel Pharmaceuticals plc (Avadel) employees which vested in full upon the closing of the transaction.

• During the quarter, the company recorded a change in the fair value of contingent consideration of $26.4 million, related to the CVR milestone associated with the acquisition of Avadel, which was deemed more likely to be achieved following the recently announced positive topline results of the phase 3 study of LUMRYZ in idiopathic hypersomnia.

Balance Sheet

• At June 30, 2026, the company recorded cash, cash equivalents and total investments of $691.6 million, compared to $538.2 million at March 31, 2026.²

Financial Expectations for 2026

All line items are according to GAAP, except as otherwise noted.

Conference Call

Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026, to discuss these financial results and expectations and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes’ website.

About Alkermes plc

Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.³

Non-GAAP Financial Measures... (truncated)rdance with generally accepted accounting principles in the U.S. (GAAP), including EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes share-based compensation expense and non-recurring gains or losses in addition to the components of EBITDA from earnings.

The company’s management and board of directors utilize these non-GAAP financial measures to evaluate the company’s performance. The company provides these non-GAAP financial measures of the company’s performance to investors because management believes that these non-GAAP financial measures, when viewed with the company’s results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, EBITDA and Adjusted EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, EBITDA and Adjusted EBITDA should not be considered measures of the company’s liquidity.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

Financial statements

Income Statement

Three Months Ended June 30, — Revenues (in millions)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Total Revenues496390.7888.9697.2
Total Proprietary Net Sales411.7307.2749.8551.7
VIVITROL®124.5121.7236.9222.7
ARISTADA®i96.7101.3190.5174.8
LYBALVI®9484.3186.3154.3
LUMRYZ®96.6$—136.1$—

Income Statement

Previous 2026 Expectations (provided May 5, 2026) — All line items are according to GAAP, except as otherwise noted. (in millions)

Previous 2026 Expectations (provided May 5, 2026)Updated 2026 Expectations (provided July 28, 2026)
Total Revenues$1,730 – $1,840$1,730 – $1,840
VIVITROL Net Sales$460 – $480$460 – $480
LYBALVI Net Sales$380 – $400$380 – $400
ARISTADAi Net Sales$365 – $385$365 – $385
LUMRYZ Net Sales a$315 – $335$315 – $335
Cost of Goods Sold b$320 – $340$320 – $340
R&D Expenses$445 – $485$445 – $485
SG&A Expenses$890 – $930$890 – $930
Amortization of Intangible Assets c$75 – $85$75 – $85
Change in the Fair Value of Contingent Consideration d~$25
Net Interest Expense$75 – $85$75 – $85
Net Tax Benefit~$0~$0
GAAP Net Loss e($70) – ($90)($95) – ($115)
EBITDA f$105 – $135$75 – $95
Adjusted EBITDA f$370 – $410$370 – $410

Income Statement

(tables follow)

Alkermes plc and Subsidiaries – Selected Financial Information (Unaudited) – Three Months Ended – June 30, 2026Alkermes plc and Subsidiaries – Selected Financial Information (Unaudited) – Three Months Ended – June 30, 2025
Revenues:Product sales, net411,724307,235
Revenues:Manufacturing and royalty revenues84,28583,422
Revenues:Total Revenues496,009390,657
Expenses:Cost of goods manufactured and sold98,11249,460
Expenses:Research and development112,92077,370
Expenses:Selling, general and administrative217,625170,849
Expenses:Amortization of acquired intangible assets22,585
Expenses:Change in the fair value of contingent consideration26,414
Expenses:Total Expenses477,656297,679
Expenses:Operating Income18,35392,978
Other (Expense) Income, net:Interest income5,34411,090
Other (Expense) Income, net:Interest expense-25,925
Other (Expense) Income, net:Other income, net352771
Other (Expense) Income, net:Total Other (Expense) Income, net-20,22911,861
Other (Expense) Income, net:(Loss) Income Before Income Taxes-1,876104,839
Other (Expense) Income, net:Income Tax (Benefit) Provision-2,37717,741
Other (Expense) Income, net:Net Income — GAAP50187,098
Other (Expense) Income, net:Earnings Per Share - Basic00.53
Other (Expense) Income, net:Earnings Per Share - Diluted00.52
Weighted Average Number of Ordinary Shares Outstanding:Basic167,026164,959
Weighted Average Number of Ordinary Shares Outstanding:Diluted173,478168,357
An itemized reconciliation between net income on a GAAP basis and Adjusted EBITDA is as follows:Net Income — GAAP50187,098
Adjustments:Interest income-5,344-11,090
Adjustments:Interest expense25,925
Adjustments:Income tax provision-2,37717,741
Adjustments:Depreciation expense7,6937,818
Adjustments:Amortization of acquired intangible assets22,585
Adjustments:EBITDA48,983101,567
Adjustments:Share-based compensation31,29624,966
Adjustments:Costs related to the acquisition of Avadel32,525
Adjustments:Change in the fair value of contingent consideration26,414
Adjustments:Adjusted EBITDA139,218126,533

Income Statement

(tables follow)

Alkermes plc and Subsidiaries – Selected Financial Information (Unaudited) – Six Months Ended – June 30, 2026Alkermes plc and Subsidiaries – Selected Financial Information (Unaudited) – Six Months Ended – June 30, 2025
Revenues:Product sales, net749,838551,728
Revenues:Manufacturing and royalty revenues139,082145,439
Revenues:Total Revenues888,920697,167
Expenses:Cost of goods manufactured and sold159,69098,657
Expenses:Research and development216,265149,187
Expenses:Selling, general and administrative482,218342,553
Expenses:Amortization of acquired intangible assets34,260
Expenses:Change in the fair value of contingent consideration26,414
Expenses:Total Expenses918,847590,397
Expenses:Operating (Loss) Income-29,927106,770
Other (Expense) Income, net:Interest income13,88321,231
Other (Expense) Income, net:Interest expense-46,817
Other (Expense) Income, net:Other (expense) income, net-9412,327
Other (Expense) Income, net:Total Other (Expense) Income, net-33,87523,558
Other (Expense) Income, net:(Loss) Income Before Income Taxes-63,802130,328
Other (Expense) Income, net:Income Tax Provision2,17720,766
Other (Expense) Income, net:Net (Loss) Income — GAAP-65,979109,562
Other (Expense) Income, net:(Loss) Earnings Per Share - Basic-0.40.67
Other (Expense) Income, net:(Loss) Earnings Per Share - Diluted-0.40.65
Weighted Average Number of Ordinary Shares Outstanding:Basic166,613164,188
Weighted Average Number of Ordinary Shares Outstanding:Diluted166,613168,470
An itemized reconciliation between net (loss) income on a GAAP basis and Adjusted EBITDA is as follows:Net (Loss) Income — GAAP-65,979109,562
Adjustments:Interest income-13,883-21,231
Adjustments:Interest expense46,817
Adjustments:Income tax provision2,17720,766
Adjustments:Depreciation expense15,44615,239
Adjustments:Amortization of acquired intangible assets34,260

Income Statement

(tables follow)

2026 Guidance — GAAP to EBITDA and Adjusted EBITDA – Alkermes plc and Subsidiaries – An itemized reconciliation between projected net loss on a GAAP basis, EBITDA and Adjusted EBITDA is as follows: – Amount
Projected Net Loss — GAAP-105
Adjustments:Net interest expense80
Adjustments:Depreciation and amortization expense110
Adjustments:Projected EBITDA85
Adjustments:Share-based compensation expense125
Adjustments:Costs related to the acquisition of Avadel155
Adjustments:Change in the fair value of contingent consideration25
Adjustments:Projected Adjusted EBITDA390
Adjustments:Projected Net Loss on a GAAP basis and Projected EBITDA and Projected Adjusted EBITDA reflect mid-points within ranges of estimated guidance.Projected Net Loss on a GAAP basis and Projected EBITDA and Projected Adjusted EBITDA reflect mid-points within ranges of estimated guidance.

Balance Sheet

(tables follow)

Alkermes plc and Subsidiaries – Selected Financial Information (Unaudited) – June 30, – 2026Alkermes plc and Subsidiaries – Selected Financial Information (Unaudited) – December 31, – 2025
Cash, cash equivalents and total investments691,631588,360
Restricted cash731,206
Receivables456,477334,025
Inventory298,957196,625
Prepaid expenses and other current assets110,89579,090
Property, plant and equipment, net218,284221,722
Intangible assets, net1,761,456815
Goodwill594,27383,027
Deferred tax assets123,041125,815
Other assets138,111126,308
Total Assets4,393,1252,486,993
Accrued sales discounts, allowances and reserves295,645247,126
Long-term debt, current portion26,500
Other current liabilities339,946296,311
Long-term debt1,476,611
Other long-term liabilities445,873124,261
Total shareholders' equity1,808,5501,819,295
Total Liabilities and Shareholders' Equity4,393,1252,486,993
Ordinary shares outstanding (in thousands)167,541165,607
Full release

Note Regarding Forward-Looking Statements

Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company’s expectations concerning its future financial and operating performance, business plans or prospects, including expectations related to revenue, growth, profitability and value creation; and expectations regarding development timelines for, and the potential therapeutic and commercial value of, alixorexton and the company’s other development candidates. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the company may not be able to achieve its financial expectations, including those related to revenue, growth, profitability and value creation; clinical development activities may not be completed on time or at all; the results of the company’s development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; the unfavorable outcome of arbitration, litigation, or other proceedings or disputes related to the company’s products or products using the company’s proprietary technologies; the company’s products or product candidates could be shown to be ineffective or unsafe; the U.S. Food and Drug Administration or regulatory authorities outside the U.S. may not agree with the company’s regulatory approval strategies or components of its development programs and may make adverse decisions regarding the company’s products; the company and its licensees may not be able to continue to successfully commercialize their products or support revenue growth from such products; potential changes in the competitive landscape impacting our products, including earlier than anticipated entry of competition from generic forms of our products or competitive products and negotiated maximum fair pricing of competitive products; potential changes in the cost, scope and duration of the company’s development programs; the businesses of Alkermes and Avadel may not be effectively integrated and the expected benefits and value of the acquisition may not be achieved; there may be unknown or inestimable liabilities and potential litigation associated with the acquisition; there may be a reduction in payment rate or reimbursement for the company’s products or an increase in the company’s financial obligations to government payers; the company’s products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2025 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission⁴

(SEC), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA®, ARISTADA INITIO® and LYBALVI® are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; LUMRYZ® is a registered trademark of Flamel Ireland Limited, an affiliate of Alkermes plc; BYANNLI®, INVEGA HAFYERA®, INVEGA TRINZA®, TREVICTA®, XEPLION® and RISPERDAL CONSTA®, are registered trademarks of Johnson & Johnson or its affiliated companies; and VUMERITY® is a registered trademark of Biogen MA Inc., used by Alkermes under license.

(tables follow)⁵⁶⁷⁸⁹¹⁰

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.